EN
中文 EN
Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): a multicenter phase 3 study

Release date：July 03, 6057

Announcer：Burning Rock


Previous:

Next: Burning Rock Received Breakthrough Device Designation from China’s NMPA for its Multi-Cancer Early Detection Test

Recommended News
May 21, 2025
Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort
July 03, 7219
Perioperative nivolumab and chemotherapy in locally advanced squamous cell carcinoma of the oesophagus: a randomized multicentre phase 2 study with circulating tumor DNA dynamics monitoring
March 28, 2025
Cost-Effective Identification of Hepatocellular Carcinoma from Cirrhosis or Chronic Hepatitis Virus Infection Using Eight Methylated Plasma DNA Markers
March 28, 2025
Mutation-guided chemotherapy-free strategy in first-line immunotherapy for low PD-L1-expressing non-squamous NSCLC
Contact Our Experts
We would like to collect certain personal information about you through cookies and similar technologies in order to personalize the site for you, improve the performance of the site, and support our marketing efforts. By clicking “Accept All”, you confirm that we have your consent to collect and process your personal information in accordance with our Privacy Policy, which may include online targeted and social media advertising in some instances. You can by clicking “Reject All”, you can reject all cookies except for Strictly Necessary Cookies."